2024-03-28T09:45:22Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/89922023-02-20T14:07:44Zcom_20.500.12105_15322com_20.500.12105_2051com_20.500.12105_2060com_20.500.12105_2052com_20.500.12105_2053col_20.500.12105_16968col_20.500.12105_2061col_20.500.12105_2054
00925njm 22002777a 4500
dc
Rondy, Marc
author
Kissling, Esther
author
Emborg, Hanne-Dorthe
author
Gherasim, Alin Manuel
author
Pebody, Richard
author
Trebbien, Ramona
author
Pozo Sanchez, Francisco
author
Larrauri, Amparo
author
McMenamin, Jim
author
Valenciano, Marta
author
I-MOVE/I-MOVE+ group
author
Delgado-Sanz, Concepcion
author
Oliva Dominguez, Jesus Angel
author
Casas Flecha, Inmaculada
author
2018
Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates.
Euro Surveill. 2018 Mar;23(9):18-00086.
1560-7917
http://hdl.handle.net/20.500.12105/8992
29510782
10.2807/1560-7917.ES.2018.23.9.18-00086
1560-7917
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
Europe
Case control study
Influenza
Influenza vaccination
Influenza vaccine effectiveness
Multicentre study
Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies